Abstract:Hypertension represents one of the primary and most common risk factors leading to the development of heart failure (HF) across the entire spectrum of left ventricular ejection fraction. A large body of evidence has demonstrated that adequate blood pressure (BP) control can reduce cardiovascular events, including the development of HF. Although the pathophysiological and epidemiological role of hypertension in the development of HF is well and largely known, some critical issues still deserve to be clarified, including BP targets, particularly in HF patients. Indeed, the management of hypertension in HF relies on the extrapolation of findings from high-risk hypertensive patients in the general population and not from specifically designed studies in HF populations. In patients with hypertension and HF with reduced ejection fraction (HFrEF), it is recommended to combine drugs with documented outcome benefits and BP-lowering effects. In patients with HF with preserved EF (HFpEF), a therapeutic strategy with all major antihypertensive drug classes is recommended. Besides commonly used antihypertensive drugs, different evidence suggests that other drugs recommended in HF for the beneficial effect on cardiovascular outcomes exert advantageous blood pressure-lowering actions. In this regard, type 2 sodium glucose transporter inhibitors (SGLT2i) have been shown to induce BP-lowering actions that favorably affect cardiac afterload, ventricular arterial coupling, cardiac efficiency, and cardiac reverse remodeling. More recently, it has been demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Other proposed agents, such as endothelin receptor antagonists, have provided contrasting results in the management of hypertension and HF. A novel, promising strategy could be represented by small interfering RNA, whose actions are under investigation in ongoing clinical trials.

Vaccines against angiotensin receptors as a potential treatment for hypertension

Recent advancements in targeting the immune system to treat hypertension

Targeting Hypertension: A Review on Pathophysiological Factors and Treatment Strategies

Hypertension and Heart Failure: From Pathophysiology to Treatment

Interventional procedures and future drug therapy for hypertension

Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy

Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review

Autonomic Nervous System: A Therapeutic Target for Cardiac End-Organ Damage in Hypertension

Resolvin D1 as a novel target in the management of hypertension

Immunological insights into hypertension: unraveling triggers and potential therapeutic avenues

New and developing pharmacotherapies for hypertension

Latest Knowledge on the Role of Vitamin D in Hypertension

Gene editing of angiotensin for blood pressure management

Immune mechanisms in the pathophysiology of hypertension

Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?

Non-pharmacological management of hypertension

Renal Sympathetic Denervation - A Review of Applications in Current Practice

Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

Options for patients with out-of-control blood pressure: after all avenues have been exhausted